GlobeNewswire PharmaOriginal article
Efficacy of aprocitentan in patients across the cardiometabolic disease spectrum including obesity to be presented at AHA Hypertension
ConferenceaprocitentanPositive
AI Analysis
Summary
Aprocitentan efficacy data will be presented at AHA Hypertension conference, showing substantial antihypertensive benefits in patients with obesity and across the cardiometabolic disease spectrum.
Outcome Details
New analyses showing substantial antihypertensive efficacy of aprocitentan in patients with obesity and cardiometabolic disease spectrum
Importance:5/10
Sentiment:
0.60
hypertensionobesitycardiometabolic diseaseAHA conferenceefficacy data
Related Companies
Read the original article
Published by GlobeNewswire Pharma on October 5, 2026 3:45 PM